Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
Crossref DOI link: https://doi.org/10.1007/s12185-017-2281-6
Published Online: 2017-06-22
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iida, Shinsuke
Suzuki, Kenshi
Kusumoto, Shigeru
Ri, Masaki
Tsukada, Nobuhiro
Abe, Yu
Aoki, Masayuki
Inagaki, Mitsuo
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
License valid from 2017-06-22